Curatis Achieves 30% Sales Growth & Expands C-PTBE-01 Patient Reach
Curatis Holding AG (SIX:CURN, ‘Curatis’) has reported strong business performance in 2024, achieving business revenues of CHF 6.9 million, with Curatis AG contributing to these figures for only eight months. Notably, Curatis AG experienced a 30% increase in sales in its distribution business, reaching CHF 9.5 million for the full year 2024 compared to 2023.
Key Highlights
- Curatis has significantly increased its estimated patient target group for its lead project, C-PTBE-01, by a factor of 20.
- The company can apply for a biologics license for C-PTBE-01, which would grant 12 years of market exclusivity in the United States.
- The expanded indications include peritumoral brain edema (PTBE) in both children and adults with primary and metastatic brain tumors.
- A pivotal Phase III trial for C-PTBE-01 is under discussion with the US Food and Drug Administration (FDA), with a meeting planned for Q2 2025.
- Curatis maintains a strong financial position with CHF 3 million in cash at the end of 2024, supporting ongoing operations and development activities.
Business Development & Financial Performance
In 2024, Curatis generated CHF 6.4 million from product revenue and CHF 0.5 million from service revenue. Since Curatis AG was acquired on April 26, 2024, its contributions are included for only eight months. When extrapolated for the full year, Curatis AG’s distribution business grew from CHF 7.3 million in 2023 to CHF 9.5 million in 2024, reflecting an impressive 30% increase. This growth was driven by organic expansion and newly launched products.
Curatis follows a strategic model of supporting products during their registration phase and later assuming responsibility for their distribution. The company also acquires products from competitors, strengthening its market presence. The operating loss for the period amounted to CHF 3.3 million, which includes several non-cash and one-time expenses such as personnel costs associated with the revaluation of Curatis AG’s longstanding option plan (CHF 2.5 million) and one-time transaction costs (CHF 1.3 million).
Financial Overview (in CHF millions):
| Metric | 31 Dec 2024 | 31 Dec 2023 |
|---|---|---|
| Revenues | 6.9 | 0 |
| Operating Result | (3.3) | (16.3) |
| Non-Cash Costs | (2.5) | (12.4) |
| Transaction Costs | (1.3) | 0 |
| Cash & Equivalents | 3.0 | 0 |
Curatis maintains a robust financial standing, with CHF 3.0 million in cash reserves as of December 31, 2024. The positive cash flow from Curatis AG’s operations, combined with a lean organizational structure, ensures financial stability.
C-PTBE-01: Expanded Patient Target Group
On November 14, 2024, announced plans to seek approval for its lead project, C-PTBE-01, through the Biologics License Application (BLA) route. Initially focused on treating PTBE in children with diffuse midline glioma (DMG), it has now expanded the scope to include both pediatric and adult patients with PTBE in primary and metastatic brain tumors. The company is preparing to conduct a study in adult patients with PTBE following its pediatric trial.
This strategic shift has significantly increased the estimated patient population from fewer than 1,000 (children with DMG alone) to approximately 20 times that number in the U.S., with similar expansions expected in other regions.
Outlook for 2025
remains optimistic about continued sales and earnings growth in 2025. The first months of 2025 have aligned with budget projections, and the company is confident in its ability to further increase revenue.
CMC (Chemistry, Manufacturing, and Controls) development for C-PTBE-01 is progressing as planned. The first batch of the active pharmaceutical ingredient has been produced, and discussions with the FDA regarding a pivotal Phase III trial are scheduled for Q2 2025. it is also in preliminary discussions with potential partners, which will be further developed after the FDA meeting.
For more details, refer to the Curatis annual report and management report, available on the company’s website at www.curatis.com.
Additional Information on C-PTBE-01
Peritumoral brain edema (PTBE) is a severe condition associated with primary and metastatic brain tumors. The accumulation of extracellular fluid around the tumor leads to indirect impairment of brain function, causing symptoms such as:
- Headaches
- Vomiting
- Neurological dysfunctions (e.g., paralysis, speech disorders, visual disturbances)
- Cognitive impairments
PTBE can be life-threatening, making effective treatment essential.
The standard treatment for PTBE involves corticosteroids, which often cause severe side effects, including:
- Myopathy and muscle wasting
- Abnormal weight gain
- Osteoporosis
- Gastrointestinal issues (gastritis, bleeding)
- Hypertension
- Psychological changes
C-PTBE-01 has demonstrated a strong steroid-sparing effect in clinical safety and efficacy studies, potentially reducing or even eliminating the need for corticosteroids. This can significantly improve patients’ quality of life by mitigating the severe side effects associated with long-term steroid use.
About Curatis
Curatis Holding AG is a Switzerland-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for severe medical conditions. The company focuses on high-value therapeutics in areas of significant unmet medical need. With a strong financial foundation, an expanding product portfolio, and a commitment to cutting-edge medical advancements, Curatis continues to drive growth and innovation in the healthcare sector.
